Furthermore, the targeted inhibition of DNA repair machinery notably using PARP inhibitors (e.g., Niraparib, Veliparib and Olaparib, currently tested with BRCA1/2mut breast, ovarian and prostate cancers 60, 61) could be especially beneficial for treating HPV-positive cancer patients. Here, BRCA1 is linked to prostate carcinoma.